Ann: CEO presentation to Broker Meets Biotech - Perth, page-55

Simple. There is still a low demand for our shares.
In Australia the market is very illiquid compared to the US. Probably, in the more efficient US we would be worth already a couple hundreds million as a Phase II company. But Australia is a peripheral market and we are seeing as such.
We will see if some interested parties are going soon to show up in the market (and not wIth pre built and pre signed low prIced cross trades), and a true demand and value wIll raIse.
We can just wait and wish the best for the incoming investors.